Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Share-based Compensation (2019 - 2025)

Biodesix (BDSX) has disclosed Share-based Compensation for 7 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 15.02% year-over-year to $1.1 million, compared with a TTM value of $4.1 million through Dec 2025, down 37.65%, and an annual FY2025 reading of $4.1 million, down 37.65% over the prior year.
  • Share-based Compensation was $1.1 million for Q4 2025 at Biodesix, up from $1.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.6 million in Q1 2024 and bottomed at $539000.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $1.4 million, with a median of $1.2 million recorded in 2024.
  • Peak annual rise in Share-based Compensation hit 1286.0% in 2021, while the deepest fall reached 64.35% in 2021.
  • Year by year, Share-based Compensation stood at $1.3 million in 2021, then soared by 63.93% to $2.1 million in 2022, then crashed by 47.95% to $1.1 million in 2023, then increased by 17.02% to $1.3 million in 2024, then fell by 15.02% to $1.1 million in 2025.
  • Business Quant data shows Share-based Compensation for BDSX at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $1.0 million in Q2 2025.